JUBITRAN OD 2.5mg price in UAE

Overview

Welcome to Dwaey, specifically on JUBITRAN OD 2.5mg Tablets/Orodispersible page.
This medicine contains an important and useful components, as it consists of Zolmitriptan.
JUBITRAN OD 2.5mg is available in the market in concentration 2.5mg/Tablet and in the form of Tablets/Orodispersible.

PHARMAX PHARMACEUTICALS FZ LLC is the producer of JUBITRAN OD 2.5mg and it is imported from UAE, The most popular alternatives of JUBITRAN OD 2.5mg are listed downward .

Mode Of Action

Zolmitriptan is a selective agonist for serotonin (5HT1 receptors). It relieves migraine by selective constriction of intracranial blood vessels, neuropeptide release inhibition and decreased transmission in the trigeminal pain pathway.

Indication

Acute migraine attacks

Precaution

Use only if there is a clear diagnosis of migraine; exclude other potentially serious neurological conditions. Monitor BP closely. May impair ability to drive or operate machinery. Pregnancy and lactation. Child. Moderate to severe hepatic impairment. Prior CV evaluation for patients with risk factors of coronary heart disease; admin of first dose under close supervision and ECG if satisfactory CV assessment in these patients. Periodic CV evaluation for patients with risk factors of coronary arteries on zolmitriptan. Avoid oral disintegrating formulation for patients with phenylketouria. Long term use may cause accumulation of zolmitriptan in melanin rich tissue (e.g. eye). Lactation: unknown, use caution

Side Effects

1-10% Dizziness (6-10%)
Neck/throat/jaw pain (4-10%)
Parasthesia (5-9%)
Nausea (4-9%)
Weakness (3-9%)
Somnolence (5-8%)
Warm/cold sensation (5-7%)
Xerostomia (3-5%)
Chest pain (2-4%)
Diaphoresis (3%)
Pain (2-3%)
Dyspepsia (1-3%)
Dysphagia (2%)
Myasthenia (2%)
Palpation (2%)
Vertigo (2%)
Hypoesthesia (1-2%)
Myalgia (1-2%) <1% QT prolongation
Bradycardia
Tachycardia
Thrombophlebitis
Postural hypotension
Hyperglycemia
Alk phos increased
Arthritis
Twitching
Myocardial infarction and artery vasospasm in patients with CAD risk factors Potentially Fatal: Cardiac arrhythmias
MI
subarachnoid haemorrhage.

Contra indication

Patients at risk of coronary artery disease (post-menopausal women, men >40 yr, hypertension, hypercholesterolemia, smoking, obesity, DM, family history of coronary artery disease) unless evaluated. Wolff-Parkinson-White syndrome; arrhythmias associated with accessory cardiac conduction pathways; previous cerebrovascular accident; uncontrolled or severe hypertension; ischaemic heart disease, history of MI, coronary vasospasm, transient ischaemic attack. Basilar or hemiplegic migraine.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Increased risk of serotonin syndrome with SSRI, selective serotonin- and norepinephrine-reuptake inhibitors (SNRI). Increased zolmitriptan concentrations with cimetidine, quinolone antibacterials and drugs that inhibit the cytochrome P450 isoenzyme CYP1A2. Potentially Fatal: Increased risk of fatal serotonin syndrome with sibutramine. Increased risk of serotonin syndrome with MAOI and reversible inhibitors of monoamine oxidase type-A (RIMA); do not use zolmitriptan during and for 2 wk after the use of MAOI and RIMAs Do not use within 24 hr of treatment with another 5-HT1 agonist. Increased risk of additive vasoconstriction with ergot alkaloids; zolmitriptan should not be taken within 24 hr of any ergotamine or ergot-type medication.